Haemonetics (HAE)
(Delayed Data from NYSE)
$95.86 USD
+3.26 (3.52%)
Updated May 10, 2024 04:00 PM ET
After-Market: $95.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Price, Consensus and EPS Surprise
HAE 95.86 +3.26(3.52%)
Will HAE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for HAE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HAE
Haemonetics (HAE) Q4 Earnings Top Estimates, Margins Expand
Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say
HAE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
PHG vs. HAE: Which Stock Is the Better Value Option?
Exploring Analyst Estimates for Haemonetics (HAE) Q4 Earnings, Beyond Revenue and EPS
Other News for HAE
4 Analysts Assess Haemonetics: What You Need To Know
Haemonetics Corp (HAE) Fiscal 2024 Earnings: Aligns with EPS Projections, Reveals Robust ...
Wall Street Analysts Are Bullish on Top Healthcare Picks
Haemonetics price target raised by $2 at Barrington, here's why
Haemonetics price target raised by $20 at JMP Securities, here's why